KalVista Grants Pendopharm Rights to Commercialize its Angioedema Treatment in Canada-February 2024-www.financetom.com

KalVista Grants Pendopharm Rights to Commercialize its Angioedema Treatment in Canada

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

KalVista Grants Pendopharm Rights to Commercialize its Angioedema Treatment in Canada

Jun 26, 2025 5:21 AM

07:51 AM EDT, 06/26/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Thursday it has entered a licensing deal with Pendopharm to manage regulatory approval and commercialization of sebetralstat for hereditary angioedema in Canada.

The company did not disclose the financial terms of the agreement.

KalVista shares were more than 3% higher in premarket trading.

Previous page： AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment Next page： Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

Oct 18, 2025

By Mrinalika Roy Oct 18 (Reuters) - AstraZeneca ( AZN ) and Daiichi Sankyo's ( DSKYF ) drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday. The findings from both trials, presented at the European Society for Medical Oncology Congress, indicate that...

Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients

Oct 18, 2025

Oct 18 (Reuters) - Pfizer ( PFE ) and Japanese firm Astellas' drug Padcev, combined with Merck's ( MRK ) Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the companies said on Saturday. The late-stage trial studied patients with muscle-invasive bladder cancer (MIBC) who were ineligible for or declined...

Kering nearing sale of beauty business to L'Oreal, sources say

Oct 18, 2025

MILAN/NEW YORK, Oct 18 (Reuters) - French luxury group Kering, owner of fashion brand Gucci, is nearing a sale of its beauty division to L'Oreal, according to two people familiar with the situation. One source confirmed the deal would be worth around $4 billion, as per an earlier report by the Wall Street Journal, which was first to break the...

US court orders spyware company NSO to stop targeting WhatsApp, reduces damages

Oct 18, 2025

WASHINGTON (Reuters) -A U.S. court has ordered Israel's NSO Group to stop targeting Meta Platforms' WhatsApp messaging service, a development the spyware company warned could put it out of business. In a 25-page ruling handed down Friday, U.S. District Court Judge Phyllis Hamilton imposed a permanent injunction on NSO Group's efforts to break into WhatsApp, one of the world's most...